Inhibition by terbutaline of nitric oxide and superoxide anion levels of endotoxin-induced organs injury in the anesthetized rat.
Despite the fact that septic shock is characterized by a decrease in systemic vascular resistance, the main cause of death is due to multiple organ failure. The organ dysfunction is usually attributed to cell death caused by overproduction of free radicals derived from inflammation. In the host infected by endotoxin (lipopolysaccharide, LPS), the expression and release of proinflammatory tumor necrosis factor-alpha (TNF-alpha) rapidly increases, and the formation of free radicals (e.g., superoxide anion [O2*-] and nitric oxide [NO*] in the present study) are inevitably overproduced. In this study, we present evidence that overall treatment of LPS rats with terbutaline, a beta2-adrenoceptor agonist, attenuates the delayed hypotension and ameliorates the tachycardia. Overproduction of TNF-alpha and NO* (produced by inducible NO synthase [iNOS] examined by Western blot analysis in the lung and the liver) is inhibited by treatment of LPS rats with terbutaline. In addition, treatment of endotoxemic rats with terbutaline also reduces the O2*- levels in the lung and the liver. Terbutaline also improves the liver (assessed by aspartate aminotransferase, alanine aminotransferase, total bilirubin, and albumin/globulin) and kidney (assessed by creatinine and uric acid) dysfunction induced by endotoxin. These findings suggest that the amelioration of circulatory failure and organs injury by terbutaline is associated with its suppression in TNF-alpha, O2*- and NO (via iNOS) production in animals with endotoxic shock.
Liaw
Wen-Jinn
WJ
Department of Anesthesiology, Tri-Service General Hospital, Taipei, Republic of China, Taiwan.
Tzao
Chin
C
Wu
Jeng-Yuan
JY
Chen
Shiu-Jen
SJ
Wang
Jih-Hsin
JH
Wu
Chin-Chen
CC
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D004731:Endotoxins / Q000633:toxicity*; D006439:Hemodynamics / Q000187:drug effects / Q000502:physiology*; D007700:Kinetics; D008070:Lipopolysaccharides / Q000633:toxicity*; D008297:Male; D009569:Nitric Oxide / Q000037:antagonists & inhibitors / Q000097:blood*; D051381:Rats; D011921:Rats, Inbred WKY; D012772:Shock, Septic / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology*; D013481:Superoxides / Q000037:antagonists & inhibitors / Q000378:metabolism*; D013726:Terbutaline / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism*
D004731:Endotoxins; D008070:Lipopolysaccharides; D014409:Tumor Necrosis Factor-alpha; D013481:Superoxides; D009569:Nitric Oxide; D013726:Terbutaline